{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:01:15Z","timestamp":1793221275258,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jacadv.2024.100880","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T17:22:22Z","timestamp":1710177742000},"page":"100880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3066-8947","authenticated-orcid":false,"given":"Marianne","family":"Gwechenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Bar\u00f3n-Esquivias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim A.C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1635","authenticated-orcid":false,"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius C.","family":"Manu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.G.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wienerroither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Pecen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":false,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2024.100880_bib1","first-page":"483","article-title":"Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist's perspective","volume":"33","author":"Ravera","year":"2020","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.jacadv.2024.100880_bib2","article-title":"Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD - AF registry","volume":"8","author":"Goto","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2024.100880_bib3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","article-title":"Pathophysiology of atrial fibrillation and chronic kidney disease","volume":"117","author":"Ding","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2024.100880_bib4","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100880_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","article-title":"Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial\u00a0Fibrillation in Europe (ETNA-AF-Europe) study","volume":"20","author":"De Caterina","year":"2019","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jacadv.2024.100880_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","article-title":"Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)","volume":"19","author":"De Caterina","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacadv.2024.100880_bib7","doi-asserted-by":"crossref","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","article-title":"Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study","volume":"7","author":"de Groot","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacadv.2024.100880_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","article-title":"Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care","volume":"9","author":"Kirchhof","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacadv.2024.100880_bib9","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.jacc.2015.03.577","article-title":"Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial","volume":"65","author":"Bohm","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100880_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jacadv.2024.100880_bib12","article-title":"Non-vitamin K antagonist oral anticoagulants provide less adverse renal outcomes than warfarin in non-valvular atrial fibrillation: a systematic review and MetaAnalysis","volume":"10","author":"Sitticharoenchai","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2024.100880_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/jth.13229","article-title":"Anticoagulation-related nephropathy","volume":"14","author":"Wheeler","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jacadv.2024.100880_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100880_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacadv.2024.100880_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2016.10.069","article-title":"Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF","volume":"69","author":"Patti","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.100880_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2478\/jtim-2018-0005","article-title":"Do statins induce or protect from acute kidney injury and chronic kidney disease: an update review in 2018","volume":"6","author":"Verdoodt","year":"2018","journal-title":"J\u00a0Transl Int Med"},{"key":"10.1016\/j.jacadv.2024.100880_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34632-z","article-title":"Effect of statins on renal function in chronic kidney disease patients","volume":"8","author":"Hu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2024.100880_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MOL.0000000000000176","article-title":"LDL-cholesterol lowering and renal outcomes","volume":"26","author":"Waters","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacadv.2024.100880_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.100880_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24000589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X24000589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:59:40Z","timestamp":1757426380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X24000589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2772963X24000589"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.100880","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.100880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100880"}}